Overview, Prevention, and Treatment of Rabies by Nigg, Andrea Julia & Walker, Pamela L.
Overview, Prevention, and Treatment of Rabies
Andrea Julia Nigg, Pharm.D., and Pamela L. Walker, Pharm.D.
Each year, approximately 55,000 individuals worldwide die from an infection
due to the rabies virus. Rabies is a life-threatening disease caused by an RNA
virus that is usually transmitted to humans through bites from rabid animals.
More recently, reports of transmission by means of organ transplantation have
been reported. Since human rabies is nearly 100% fatal if prophylactic
measures are not followed, an increased awareness of who should receive
prophylaxis and when prophylaxis should be administered is necessary.
Preexposure prophylaxis entails the administration of the rabies vaccine to
individuals at high risk for exposure to rabies viruses (e.g., laboratory workers
who handle infected specimens, diagnosticians, veterinarians, animal control
workers, rabies researchers, cave explorers). Preexposure prophylaxis
involves a three-dose series of the rabies vaccine that may confer some
protection from the virus while simplifying postexposure prophylaxis
regimens. Postexposure prophylaxis consists of a multimodal approach to
decrease an individual’s likelihood of developing clinical rabies after a possible
exposure to the virus. Regimens depend on the vaccination status of the
victim and involve a combination of wound cleansing, administration of the
rabies vaccine, and administration of human rabies immune globulin. If used
in a timely and accurate fashion, postexposure prophylaxis is nearly 100%
effective. Once clinical manifestations of rabies have developed, however,
treatment options for rabies are limited, and to date, only seven individuals
have survived rabies virus infection. Treatment of clinical rabies consists of
medical support in an intensive care unit, using a multifaceted approach that
includes supportive care, heavy sedation, analgesics, anticonvulsants, and
antivirals. The recently developed Milwaukee Protocol added induction of
therapeutic coma to supportive care measures and antivirals; however, its use
has shown inconsistent outcomes.
Key Words: rabies virus, human rabies, rabies vaccine, human rabies
immune globulin, HRIG, antivirals, immunizations, Milwaukee Protocol.
(Pharmacotherapy 2009;29(10):1182–1195)
OUTLINE
Rabies Virus
Transmission
Clinical Manifestations
Diagnosis
Rabies Vaccines
Human Rabies Immune Globulin
Prevention of Human Rabies
Exposure Prevention
Preexposure Prophylaxis
Postexposure Prophylaxis
Management of Clinical Rabies
The Milwaukee Protocol
Supportive Care
Induction of Therapeutic Coma
Antiviral Therapy
Considerations for Use of the Milwaukee Protocol
Conclusion
Human rabies is a life-threatening infection
that is associated with a mortality rate of nearly
100% when appropriate prophylactic measures
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are not followed before or shortly after an
exposure. The incidence of human rabies
remains high worldwide with an estimated death
toll of 55,000 annually, despite the existence of
effective prophylaxis.1 In the United States, the
average number of deaths due to the rabies virus
has decreased from more than 100/year in the
early 20th century to approximately 2–3/year.2
To date, only seven individuals have survived
rabies virus infection after the onset of clinical
symptoms of the disease, and all except one
received some form of prophylaxis against
rabies.3–5
Rabies Virus
Human rabies is caused by nonsegmented,
antisense, single-stranded RNA viruses of the
family Rhabdoviridae and genus Lyssavirus,6 with
seven recognized genotypes.7 The genotypes
responsible for causing human rabies are types 1
and 3–7, although genotype 3 is rare (only two
human cases have been reported, both in Africa)
and causes atypical rabies symptoms such as
fatigue, confusion, and convulsions.3 The rabies
virus genome is approximately 12 kilobase pairs
in length and encodes five viral proteins:
nucleoprotein, phosphoprotein, matrix protein,
glycoprotein, and polymerase.2 The viruses are
not viable outside of hosts and are inactivated by
sunlight, heat, and dessication. Within the host,
the rabies viruses are highly neurotropic and
replicate slowly within muscle cells.8
Transmission
Although all mammals are susceptible to and
capable of transmitting the rabies virus, those
considered reservoirs of the virus include
carnivorous mammals and bats.6 Reservoirs of
the rabies virus are responsible for the long-term
existence and persistence of the virus, and
samples from various reservoirs have revealed
genetically distinct variants.9 Canines are
considered the primary vectors of the virus
worldwide and are responsible for the majority of
human rabies cases in Africa, Asia, Central
America, Eastern Europe, Russia, and South
America.3 In more developed regions, including
the United States, where the prevalence of
domestic animal vaccination is high, bats are
responsible for the majority of human rabies
cases. In South America, vampire bats are a well-
recognized source of human rabies transmission,
whereas in the United States the silver-haired bat
(Lasionycteris noctivagans) and eastern pipistrelle
(Pipistrellus subflavus) are the usual suspects.
Both bats are insectivorous and are rarely seen
near human dwellings. The silver-haired bat is
found in the majority of the continental United
States except for Florida and southern California,
whereas the eastern pipistrelle concentrates in
the eastern and Midwestern states.9 In addition
to bats, raccoons, skunks, coyotes, and foxes are
among the common reservoirs for rabies in North
America (Figure 1).2, 3
Human transmission of the rabies virus occurs
primarily through rabid animal bites, where
infected saliva penetrates the skin.6 The virus
can also be transmitted by exposure of an open
wound or mucous membrane to the saliva of a
rabid animal, although this occurs less frequently.
A remote potential of rabies infection occurs
through aerosol inhalation of the virus, although
this may only be possible in a few caves located
within the United States where bat density is
high, and high temperatures, extreme humidity,
and little ventilation exist.9
Infrequently, human-to-human transmission
has been reported. In 2004, the rabies virus was
transmitted to four transplant recipients from an
infected organ donor in Texas and three
transplant recipients from an infected donor in
Germany, all resulting in death for the organ
recipients.10, 11
Clinical Manifestations
In humans, rabies typically manifests in five
stages: incubation period, prodrome, acute
neurologic phase, coma, and death (or in rare
instances, recovery). The duration of the
incubation period ranges from a few days to
several years, but typically is 1–2 months.7, 8
Rabies viruses bind to nicotinic receptors on the
surface of muscle fibers, replicate slowly within
muscle, and travel into nerve tissue through
neuromuscular junctions.7, 8, 11 The variation in
incubation periods may be associated with the
time required to replicate within muscle tissue
and transverse into neuronal axons. Deep
lacerations or bites occurring on the head and
neck in which the virus is directly inoculated
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into nerve tissue are generally associated with
shorter incubation periods.
Once the virus attaches to the axons of nerves,
it travels in a retrograde fashion to the central
nervous system (CNS), where rapid replication
occurs. The prodromal stage of rabies begins
once the virus has traveled to the dorsal root
ganglia and CNS, when nonspecific symptoms
such as fever, headache, malaise, irritability,
nausea, and vomiting, may occur.3 Paresthesias,
pain, and pruritus may arise locally at the site of
viral entry.7, 8 The prodrome generally lasts a few
days to 2 weeks. Progression from the prodromal
stage to the acute neurologic phase is
characterized by neurologic dysfunction. At this
point the virus begins invasive replication within
the CNS, where it travels from neuron to neuron
through synaptic junctions.3 From the CNS, the
virus moves into other organs, glands, and tissues
and is copiously secreted in the saliva.
The acute neurologic phase can manifest as
encephalitic (furious) or paralytic (dumb) rabies.
Approximately 80% of patients present with the
encephalitic form, whereas the remainder suffer
from paralytic rabies.12 Encephalitic rabies
symptoms include hyperexcitability, hyperactivity,
hallucinations, excessive salivation, hydrophobia
(fear of water), and aerophobia (fear of air).3, 7
Hydrophobia and aerophobia may result from
painful laryngeal and pharyngeal spasms.8 Once
the encephalitic form of rabies presents, the
patient usually dies within 5 days.7 Patients with
the paralytic form of rabies frequently present
with limp paralysis of the limb initially exposed
to the virus. Paralysis may progress to
quadriplegia symmetrically or asymmetrically
and ultimately results in urinary and fecal
incontinence. Death results after the onset of
diaphragmatic and bulbar paralysis within a few
weeks.8 Coma occurs in the late stages of clinical
progression and is associated with multiorgan
failure regardless of the form of presentation. In
addition, hematemesis occurs in approximately
30–60% of patients during the last few hours of
life.7 Cardiac arrhythmias occur in almost all
cases, with the cause of death related to cardiac
and circulatory insufficiency.8
Diagnosis
The diagnosis of rabies involves the consider-
ation of a combination of clinical and laboratory
findings. Magnetic resonance imaging may
indicate rabies when abnormal hypersignaling is
present in the brainstem, hippocampus, or
hypothalamus regions.7 The degree of abnor-
mality may vary widely depending on the stage of
progression, and gadolidium enhancement only
occurs in late stages. Although clinical findings
should be a strong indication of rabies, a number
of other conditions have similar presentations.
Conditions mimicking the paralytic presentation
of rabies include Guillain Barré syndrome,
Japanese encephalitis, cerebral malaria, and the
West Nile virus.7, 8 Included in the differential
diagnosis for the encephalitic presentation are
tetanus (which may be caused by animal bites),
diphtheria, botulism, substance abuse, and
alcohol withdrawal with delirium tremens.
Although the distinguishing symptoms of
hydrophobia and aerophobia only occur in
rabies, a definitive diagnosis requires laboratory
findings.
Laboratory test sensitivities have extreme
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Figure 1. Causes of human rabies infections in 38 cases in the United States from 1995–2008. (From reference 2.)
Dog or mongoose 3%
Raccoon 3%
Dog 18%
Bat (Myotis [species unknown]) 3%
Big brown bat (Eptesicus fuscus) 3%
Brazilian free-tailed bat
(Tadarida brasiliensis) 26%
Silver-haired bat (Lasionycteris
noctivagans) and eastern pipistrelle
(Pipistrellus subflavus) 36%
Bat
76%
Bat (unknown) 8%
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variability for the diagnosis of rabies; results may
vary depending on the stage of clinical
progression, the individual’s antibody status, the
technique being performed, the technical skill of
the laboratory staff, and the intermittent nature
of viral shedding into bodily fluids and tissues.7, 8
The isolation of rabies viral RNA from saliva
samples or full-thickness skin biopsies obtained
from nuchal regions with reverse transcriptase
polymerase chain reaction confirms a diagnosis
of rabies. Isolation of the rabies virus from saliva
or other biological fluids (serum and cerebral
spinal fluid [CSF]) would also be indicative of a
rabies infection. Since the virus is not continu-
ously shed by infected individuals, isolation of
the virus or viral RNA may not be possible.
Individuals with a greater extent of antibody
production are less likely to have the rabies virus
isolated from bodily fluids. The detection of
rabies virus antibodies from the serum of
unvaccinated individuals through the direct
fluorescent antibody test is also diagnostic of a
rabies infection. Production of antibodies to the
rabies virus generally occurs 7–10 days after
onset of clinical symptoms, although isolation of
antibodies from sera of infected individuals may
not always occur. Isolation of rabies virus
antibodies from the CSF through the direct
fluorescent antibody test is also diagnostic
regardless of previous vaccination status, since
antibodies are too large to penetrate the blood-
brain barrier. Antibody appearance in the CSF
occurs later in the disease progression than that
in serum. To assist in rabies testing, the Center
for Disease Control and Prevention or state
health officials should be contacted, as testing
may be performed in a number of locations
depending on geographic locale.
Rabies Vaccines
Three rabies vaccines are licensed for human
use in the United States: Imovax Rabies (Sanofi
Pasteur, Swiftwater, PA), RabAvert (Novartis
Vaccines and Diagnostics, Marburg, Germany),
and rabies vaccine adsorbed (RVA; BioPort Corp.,
Lansing, MI).13 However, only Imovax Rabies
and RabAvert are manufactured for use and are
available in the United States. Imovax Rabies is a
human diploid cell vaccine prepared with the
Pitman-Moore rabies strain grown on a human
diploid cell culture. The vaccine is available in
single-dose vials with the accompanying diluent
in a prepackaged syringe.14 The current
availability of Imovax is limited due to the
renovation of the Sanofi Pasteur production
facility in France to maintain compliance with
U.S. Food and Drug Administration requirements.15
The renovated facility should be operational by
mid- to late 2009. Until that time, Imovax is
available only for postexposure prophylaxis.
RabAvert, a purified chick embryo cell vaccine,
has been available in the United States since
1997.16 It is prepared from the fixed rabies virus
strain Flury low egg passage grown in cultures of
chick fibroblasts. RabAvert is also available in a
single-dose vial with accompanying diluent.
After the start of the renovation of the Sanofi
Pasteur facility, Novartis was not able to meet the
market demand for RabAvert. Thus, from
October 2008–April 2009, RabAvert was available
only for postexposure prophylaxis. Since April
2009, however, RabAvert has been available for
both pre- and postexposure prophylaxis, without
limitations for its use.15
Both vaccines available in the United States are
preservative free and should be administered
immediately after reconstitution. For both
vaccines, the total volume of one dose is 1 ml
(regardless of indication) and should be
administered intramuscularly into the deltoid
region. In young children and infants, the
vaccines may be injected into the anterolateral
area of the thigh. Gluteal administration is not
recommended as this may result in lower
neutralizing antibody titers and may damage the
sciatic nerve.14, 17 The potency of each dose is
equal to or greater than the World Health
Organization’s recommended standard of 2.5
IU/ml.13 The dosage regimen for the rabies
vaccines depends on the indication, and these
regimens are delineated in their respective
sections below. Because both Imovax and
RabAvert are inactivated virus vaccines, no
cytotoxic T-cell response is elicited, which may
be important for viral clearance. It may take
7–10 days for the active production of viral
neutralizing antibodies to occur, although the
antibodies generally persist for several years. The
cost of one dose of either rabies vaccine is
approximately $200.18
Common adverse effects associated with the
use of either rabies vaccine include local
injection-site reactions such as erythema, itching,
swelling, and induration, and systemic reactions
such as headache, nausea, abdominal pain,
muscle aches, dizziness, and fever. The
occurrence of adverse effects should not interrupt
the vaccination schedule, as no deaths have been
reported following the use of either vaccine.
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RabAvert should be avoided in patients with
severe egg allergies since the vaccine is prepared
with chick embryos and may contain a small
amount of egg protein. Both vaccines are safe for
use during pregnancy.13, 19
Human Rabies Immune Globulin
Two human rabies immune globulin (HRIG)
products are available in the United States:
HyperRAB S/D (Talecris Biotherapeutics,
Research Triangle Park, SC) and Imogam Rabies
HT (Aventis Pasteur, Lyon, France).13 Human
rabies immune globulin provides activity against
rabies viruses by providing passive immunization
through neutralizing viral antibodies.20, 21 Both
products are preservative-free immunoglobulin G
preparations obtained from pooled plasma of
human donors hyperimmunized with the rabies
vaccine. HyperRAB S/D and Imogam Rabies HT
are supplied as sterile solutions of antirabies
immune globulin for intramuscular administration.
The minimal potency of each is 150 IU/ml, and
both products are available in 2-ml (300 IU) and
10-ml (1500 IU) vials that should be stored
under refrigeration (2–8°C). The recommended
dose for HRIG is 20 IU/kg. After intramuscular
injection, antibodies are present in the serum
within 24 hours. The antibody level peaks in
2–13 days and persists for approximately 24
days. Human rabies immune globulin should
only be used as postexposure prophylaxis in
patients who have not previously been vaccinated
with a rabies vaccine.
Human rabies immune globulin should be
administered as soon as possible after recognition
of a potential exposure to rabies. The entire dose
of HRIG should be injected directly into and
around the bite wound if feasible and if a wound
is evident; the remainder of the dose should be
given intramuscularly in the upper arm, lateral
thigh, or gluteal muscle.20, 21 Human rabies
immune globulin should not be administered
more than 7 days after the rabies vaccine, as it
may interfere with active immune response and
antibody production. Because HRIG may
interfere with the response to live vaccines, live
vaccines such as measles, mumps, polio, or
rubella should not be given within 3 months of
HRIG administration. Adverse effects of HRIG
include local injection site reactions such as
tenderness, pain, and soreness; headache;
malaise; fever; skin rash; angioneurotic edema;
nephrotic syndrome; and anaphylactic shock.
Since the HRIG products are obtained from
human donors, they have the potential to contain
other viruses, although, to our knowledge, no
transmissions have been documented. The
approximate cost of one dose of HRIG for a 70-
kg individual is $1500.18
Prevention of Human Rabies
Exposure Prevention
Due to the high mortality rate associated with
human rabies, adequate measures to ensure
prevention of transmission should be followed.
Individuals, including children, should be
educated to avoid contact with unfamiliar
animals, especially bats, in the United States. To
prevent bats from entering homes, churches,
schools, or other locations where potential
human contact may occur, openings larger than
one-quarter inch by one-half inch in buildings
should be repaired. The best times of the year to
repair bat entry sites are the fall and winter, as
young bats may be unable to fly during the
summer months and may become trapped inside
living quarters.22 If bats are found dead or alive
within living quarters, the local animal control or
public health agency should be contacted to
facilitate removal, and the animal should be
tested to determine whether medical attention
should be sought, especially if it is unknown
whether a bite may have occurred. Individuals
should also be responsible pet owners, by
maintaining current rabies vaccinations for all
pets and preventing pets from coming into
contact with wild animals by keeping them from
roaming free.9
Health care workers involved in the direct care
of patients who have had known or suspected
exposure to the rabies virus should take
precautions to ensure that they do not contract
the virus from patients. Contact precautions,
including barrier methods such as gloves,
goggles, masks, and gowns, should be used to
avoid contact with patients’ bodily substances,
mucous membranes, or open wounds, which
could theoretically lead to exposure. Although
no cases of patient-to–health care worker
transmission have been reported to date, proper
prevention of exposure is warranted.6
Preexposure Prophylaxis
The purpose of preexposure prophylaxis is to
simplify the management of patients if an
exposure to rabies occurs and to offer some
protection to individuals who may incur an
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unrecognized exposure.6 The use of proper
preexposure prophylaxis decreases the number of
rabies vaccine doses needed and eliminates the
need for HRIG administration in the case of a
possible exposure. For individuals in areas
where the safety of rabies biologics may not be as
inherent as in more developed areas, preexposure
prophylaxis reduces their exposure to potentially
harmful products and lessens their risk for
adverse effects. Preexposure prophylaxis entails
the administration of the rabies vaccine to
individuals at high risk for exposure to rabies
viruses. Those individuals include laboratory
workers who handle infected specimens,
diagnosticians, veterinarians, animal control
workers, rabies researchers, and cave explorers in
areas where the virus is common.13 Other
individuals who may frequently come into
contact with possibly rabid animals should
consider vaccination. In addition, travelers to
areas where rabies is prevalent who engage in
wilderness activities such as camping and hiking
may benefit from the vaccine, especially if the
availability of postexposure prophylaxis at the
travel destination is limited, nonexistent, or its
administration may be delayed.6
Individuals undergoing primary vaccination
should receive three 1-ml intramuscular
injections of either the purified chick embryo cell
vaccine (RabAvert) or the human diploid cell
vaccine (Imovax) product on days 0, 7, and 21 or
28 (Table 1).13 Minor deviations to this
vaccination schedule should not have an impact
on efficacy. If major deviations occur, titers
should be evaluated or the series should be
reinitiated. Previous studies have demonstrated
sufficient antibody response to rabies in healthy
individuals after primary vaccination with the
three-dose regimen administered appropriately13;
therefore, assessing antibody levels after
preexposure prophylaxis to evaluate serocon-
version is not warranted unless an individual is
immunosuppressed. Immunocompromised
patients should forgo preexposure prophylaxis
and take all precautionary measures previously
mentioned to avoid rabies exposure. If avoidance
is not feasible, the Center for Disease Control
and Prevention recommends assessing titers 1–2
weeks after completion of the three-dose series.
Titers obtained should completely neutralize the
virus at a 1:5 serum dilution or they should
exceed a level of 0.5 IU/ml. In the event a patient
fails to seroconvert, public health officials should
be consulted.
Rabies virus neutralizing antibody levels have
not been correlated to an individual’s suscepti-
bility to the rabies virus although levels do
indicate the immune status to rabies. Based on
the Advisory Committee for Immunization
Practices (ACIP) recommendations, periodic
measuring of rabies virus neutralizing antibody
levels should be performed based on an
individual’s risk for exposure. Individuals at a
continuous risk, including rabies researchers and
biologic producers, should undergo titer testing
every 6 months. Animal control and wildlife
workers, bat handlers, rabies diagnostic
laboratory workers, veterinarians and their staff,
and cave explorers fall into the frequent-risk
category for rabies exposure and should have
their titers measured every 2 years. Those
considered at infrequent risk, including
veterinarians, veterinary students, and animal
control workers in areas where rabies is
uncommon; and travelers, and those at rare risk
for exposure to rabies such as the general
population are not recommended to undergo
serologic testing or to receive booster doses. A
booster dose of the vaccine should be given to
individuals in the continuous-risk and frequent-
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Table 1. Pre- and Postexposure Prophylaxis Regimens
Type of Prophylaxis Product Regimen
Preexposure prophylaxis Rabies vaccinea 1 ml on days 0, 7, and 21 or 28
Postexposure prophylaxis Rabies vaccinea 1 ml on days 0, 3, 7, and 14b
Patients not previously vaccinated, were Human rabies 20 IU/kg (0.133 ml/kg) on days 0–7d
vaccinated > 2 yrs earlier, or whose immune globulinc
titers have decreased below 0.5 IU/ml
Patients vaccinated within previous 2 yrs Rabies vaccinea 1 ml on days 0 and 3
aImovax or RabAvert.
bFour-dose regimen recommended by the Advisory Committee for Immunization Practices in July 2009. Immunosuppressed
individuals should also receive a fifth dose on day 28.
cHyperRAB S/D or Imogam Rabies HT.
dDay 0 refers to the day of first rabies vaccine administration; earlier administration may be more efficacious.
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risk categories when their titer levels are < 0.5
IU/ml or if their titer fails to completely
neutralize virus at a 1:5 serum dilution.
Due to limited investigation into the inter-
changeability of the two vaccine products,
current recommendations suggest using the same
vaccine product for the duration of the
vaccination series; however, if an intolerable
adverse reaction occurs after the use of one
product, the other vaccine may used.6 If different
products are used within the same series, having
titers assessed 1–2 weeks after completion of the
series may be useful to ensure adequate immune
status.
Postexposure Prophylaxis
Postexposure prophylaxis consists of a
multimodal approach to decrease an individual’s
likelihood of developing clinical rabies after a
possible exposure to the virus. Wound cleansing
and administration of the rabies vaccine and
HRIG are the primary components of rabies
postexposure prophylaxis. Since the likelihood
of a rabies infection depends on the type and
extent of the exposure, thorough assessment of a
patient’s risk of infection should be undertaken
before initiation of postexposure prophylaxis
(Figure 2). Before administration of postexposure
prophylaxis, the individual’s risk factors for
exposure to rabies should be assessed. The
decision to initiate postexposure prophylaxis
should occur in a timely fashion, as delays may
increase an individual’s risk for developing
clinical rabies. When used appropriately,
postexposure prophylaxis is nearly 100%
effective.23
When individuals in the United States present
with nonbite exposures to bats, raccoons, foxes,
skunks, or coyotes, only those in which saliva,
blood, or other possible infectious substances
from the animal come into contact with open
wounds or mucous membranes warrant initiation
of postexposure prophylaxis. All bite exposures
to these animals require prophylaxis, as the
rabies virus concentrates in saliva. Under
circumstances where a bat bite may have
occurred in an individual unable to communicate
or unaware of the incident (e.g., bat found in
room of young infants, deep sleepers, or mentally
incapacitated individuals), postexposure
prophylaxis should be initiated even if a bite
wound is not evident. Whether the exposure
involved a bite or nonbite contact, the animal to
which the exposure occurred should be captured
if possible and undergo testing for rabies.
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Figure 2. Decision tree for starting and continuing rabies postexposure prophylaxis.
Patient with evident bite exposure to bat, raccoon,
skunk, coyote, or fox in the United States, or to dog
in developing countries
Initiate postexposure
prophylaxis
immediately
Continue postexposure
prophylaxis until results
available
Animal with positive rabies tests or
displays signs and symptoms of
rabies
Complete postexposure
prophylaxis regimen
Discontinue postexposure
prophylaxis
Complete postexposure
prophylaxis regimen
Patients with known mucous-membrane
or wound-salivary exposure unable
to give accurate history
Animal available for
observation or rabies
testing
No postexposure prophylaxis
warranted
Yes
Yes
Yes
Yes
No
No
No
No
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Postexposure prophylaxis should be discontinued
if the animal in question is found to have a
negative rabies test. Household pets involved in
potential human exposures should be observed
for 10 days for the presence of rabies. If rabies
symptoms do not present in the animal under
observation, postexposure prophylaxis for the
victim should be discontinued.
When a bite wound is evident or an open
wound is exposed to infectious substances, the
wound should be promptly and thoroughly
cleansed with soap and water for a minimum
duration of 15 minutes.24 The use of virucidal
antiseptics such as povidone iodine and ethanol
is advocated for initial wound treatment. Topical
antibiotics may also be considered depending on
wound severity. In addition, closure of bite or
scratch wounds should be avoided.25
Following wound cleansing, postexposure
prophylaxis regimens differ depending on the
rabies immunization status of the individual
exposed. For individuals who have not received
preexposure prophylaxis in the preceding 2 years,
HRIG should be administered immediately.6, 8, 13
A dose of 20 IU/kg (0.133 ml/kg) of either HRIG
product (HyperRAB S/D or Imogam Rabies HT)
should be administered directly into the wound
and the area surrounding the wound (Table 1). If
it is not feasible to administer the entire dose
near the wound or a wound is not apparent, any
remaining volume should be given intramuscularly
in the upper arm or lateral thigh muscle.
In addition, patients who have not been
previously vaccinated, were vaccinated more than
2 years earlier, or whose titers have dropped
below the recommended level of 0.5 IU/ml
should receive four 1-ml doses of either rabies
vaccine.6, 13, 26 The first dose should be adminis-
tered as soon as possible (day 0) at a site distant
to the administration site of HRIG, as HRIG can
interfere with the immune action of the rabies
vaccine. The vaccine and HRIG should not be
mixed in the same syringe. The remaining three
doses of vaccine should be given on days 3, 7,
and 14 after the first dose (Table 1).6, 13, 27 In July
2009, the ACIP recommendations were amended,
decreasing the number of rabies vaccine doses
required for postexposure prophylaxis from five
to four based on current evidence.26 However,
patients who are immunosuppressed should still
receive a five-dose series of the vaccine on days 0,
3, 7, 14, and 28. If HRIG was not administered
in conjunction with the first vaccine dose, it can
be given up to and including day 7 of the
vaccination series. After day 7 of the vaccination
series, an immune response should have
occurred, so the use of HRIG is no longer
warranted.
For patients who have received recent (≤ 2
years) preexposure prophylaxis, two 1-ml
intramuscular doses of the rabies vaccine should
be administered (Table 1). The first dose should
be given immediately and the second dose 3 days
later. No HRIG is warranted, as passive antibody
administration may interfere with innate
antibody production.
Deviations from HRIG administration recom-
mendations and postexposure vaccination
schedules should be minimized as much as
possible. If a minor lapse in vaccination schedule
occurs, it should be resumed by maintaining the
same time interval(s) between subsequent
scheduled doses. For example, if a patient misses
the vaccine due on day 3 and presents on day 4
for a dose, subsequent doses should be given on
days 8, 15 and 29 (vs days 7, 14, and 28) after
the first dose. The impact of large deviations
from both pre- and postexposure vaccination
schedules is unknown; therefore, deviations are
not recommended.13
Management of Clinical Rabies
To date, only seven individuals have survived
rabies, and all except one received some form of
pre- or postexposure prophylaxis before the onset
of clinical symptoms.4, 5 Patients who may have
contracted rabies should undergo postexposure
prophylaxis as soon as possible to improve their
chances of survival, although administration of
HRIG should be avoided after the onset of
symptoms. Human rabies immune globulin may
interfere with the innate immune response to an
active rabies infection and does not penetrate the
blood-brain barrier. Aside from preventing the
development of rabies with the use of pre- and
postexposure prophylaxis, no single treatment
regimen has consistently proven effective for the
management of human rabies.
A diagnosis of rabies should be confirmed by
the Centers for Disease Control and Prevention
before initiating therapy. Before aggressive
management of patients with a diagnosis of
human rabies is initiated, the patient, provider,
and family must recognize and understand that
the chances of survival are low. If the patient
survives medical management of human rabies,
they must also be aware of the high likelihood of
a poor neurologic outcome. Only two of six
rabies survivors recovered without serious
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neurologic sequelae; however, the neurologic
outcome of a Brazilian boy who recently survived
has yet to be determined.4, 5 Factors that may be
associated with better outcomes include younger
age of patient, relatively few or no concomitant
medical conditions, vaccination before the onset
of symptoms, and early presentation at the time
of treatment initiation.28
The treatment of rabies involves a multifaceted
approach including supportive care, heavy sedation,
analgesics, anticonvulsants, and antivirals.1, 28–30
The treatment of rabies entails medical support
in an intensive care unit with personnel trained
in the management of multisystem organ failure,
as this often occurs in the later stages of clinical
rabies.
The Milwaukee Protocol
A variety of approaches have been used in the
treatment of human rabies, and a recent protocol
was developed by the Medical College of
Wisconsin—the Milwaukee Protocol—after the
survival of a young patient from Wisconsin
diagnosed with rabies (Table 2).31 In the case of
this survivor, induction of a therapeutic coma in
addition to supportive care measures and
antivirals were used with success. A number of
agents were used to induce a therapeutic coma to
decrease the metabolic demands of the CNS,
theoretically reduce possible excitotoxicity of
rabies, and diminish autonomic hyperactivity
associated with progressing clinical rabies.29
After the success of the Milwaukee Protocol for
the young Wisconsin patient, several others have
employed similar treatment regimens with
minimal beneficial outcomes.30, 32
Supportive Care
Supportive care for patients with rabies consists
of several approaches to enable a patient to recover
without directly attempting to cure the patient.
Immobile patients should receive general prophy-
lactic measures for the prevention of venous
thromboembolism, stress ulcers, and pressure
ulcers. Vitamin, mineral and cofactor supplemen-
tation is recommended, as profound deficiencies
may result due to critical illness and medical
management.29 The metabolic demands of
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Table 2. Summary of the Milwaukee Protocol for Treatment of Patients with Clinical Rabies31
Treatment Agents Rationale
Supportive care Nutrition (preferably enteral), Provides the patient with support necessary to allow the
fluids (usually crystalloid) immune system to mount a response to the virus
Vitamin, mineral, and cofactor Corrects deficiencies associated with the virus
supplements (tetahydrobiopterin,
[BH4], coenzyme Q10, vitamin C
highly recommended)
Antipyretics (if body temperature Provides prophylaxis for complications that commonly occur
> 38.9°C); anticoagulants in critical illness
(s.c. heparin for prophylaxis
or i.v. heparin infusion if
thromboembolic treatment is
warranted)a
Therapeutic coma Benzodiazepines Decreases metabolic demands of cerebral tissue
Ketamine Decreases autonomic hyperactivity
Adjunct agents if needed to Reduces seizure activity, possibly decreases excitotoxicity
maintain partial burst suppression associated with rabies virus
(barbiturates, propofol)
Antivirals Amantadine, ketamineb Decreases viral load while immune system response develops
Agents to avoid Barbiturates Inhibits T-cell activation necessary for immune response
if possible against the virus
Propofol Associated with flat electroencephalogram in two cases
Rabies vaccine No apparent benefit; may slow natural immune response to
virus
Human rabies immune globulin No apparent benefit; may not penetrate blood-brain barrier
Ribavirin No in vivo evidence to support its use; may cause pancreatitis,
mitochondrial toxicity, and hemolysis; suppresses humoral
immune response; depletes BH4; does not penetrate blood-
brain barrier well
aHeparin is easily reversible in the event complications arise or if surgical procedures are warranted.
bOnly in vitro data exist to support the antiviral activity of ketamine.
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individuals significantly increase when under the
physical stresses associated with critical illness.
When hypermetabolic states are maintained for
significant periods of time, which is likely in the
case of human rabies, body stores of essential
nutrients are diminished. Recommended oral
supplementation includes creatine 3 g/day, co-
enzyme Q10 (adults 1200–2400 mg/day,
pediatrics 30–60 mg/kg/day), L-carnitine (adults
1.3 g every 8 hrs, pediatrics 100 mg/kg every 8
hrs), vitamin C (adults 500 mg/day, pediatrics
35–100 mg/day), vitamin E (200 IU/day), and
zinc sulfate (adults 2.5–5 mg/day, pediatrics
100–300 µg/kg/day) if patients are noted to be
deficient.31 Since tetrahydrobiopterin (BH4
[BioMarin Pharmaceutical Inc., Novato, CA], a
cofactor necessary for the production of
catecholamine and serotonergic neurotransmitters)
deficiency has been noted in the CSF of patients
with clinical manifestations of rabies, its
supplementation with 800 mg enterally every 8
hours (pediatrics 2 mg/kg every 8 hrs) is
recommended by the Milwaukee Protocol to
prevent deficiency from occurring. Antipyretics
may be used to assist in defervescence, although
the Wisconsin survivor exhibited no response to
acetaminophen, ibuprofen, or ketorolac. Airway
protection with intubation and mechanical
ventilation may be necessary for patients with
excessive salivation and pharyngeal and laryngeal
spasm or uncontrollable swallow reflexes.29, 30
The use of vasopressors may also be warranted to
facilitate adequate blood pressure in severe cases.
Supportive care is not limited to these options
and should also include seizure prophylaxis and
treatment, pain management, and optimal
nutrition (including correction of fluid and
electrolyte imbalances) based on the patient’s
clinical status.
Therapeutic Coma
The agents employed to induce a therapeutic
coma in the case of the Wisconsin patient
included ketamine, benzodiazepines, and
barbiturates.29 Propofol has also been used in the
management of other human rabies cases. The
rationale behind instituting a therapeutic coma
relates to decreasing the metabolic demands of
cerebral tissue, reducing autonomic hyperactivity
and possible seizure activity that may occur in
later stages of the disease, and inhibiting the
possible excitotoxicity that may occur in rabies.
If therapeutic coma induction is employed,
patients must be mechanically ventilated.
Sedation should be titrated to achieve and
maintain partial burst suppression on electro-
encephalographic (EEG) monitoring; therefore
all patients should undergo continuous EEG
monitoring.
Ketamine, a dissociative anesthetic derivative
of phencyclidine, was used in the Wisconsin
patient at an infusion rate of 2 mg/kg/hour.29
Ketamine exhibits both anesthetic and analgesic
properties and acts by noncompetitive inhibition
of the excitatory effects of glutamate at the N-
methyl-D-aspartate (NMDA) receptor.33, 34
Extensive research has demonstrated that drugs
with high affinity for the phencyclidine binding
site on the NMDA receptor possess antiviral
activity in vitro.33 The researchers concluded
that ketamine inhibits transcription of the rabies
virus genome in vitro. In vivo antiviral effects of
ketamine are yet to be determined, although its
use in the management of rabies may be benefi-
cial from a sedation and antiviral standpoint.
Ketamine is associated with emergence reactions,
which may include vivid dreams, nightmares,
and hallucinations. Ketamine may also cause an
increase in salivation, so vigilance is warranted to
avoid aspiration (which should not be a concern
if the patient is adequately intubated) and
dehydration.31 On discontinuation of a thera-
peutic coma, ketamine may be rapidly tapered by
halving the infusion rate every 12 hours until a
rate of 0.5 mg/kg/hour is attained.
Benzodiazepines have been used in a number
of cases to aid in the maintenance of a therapeutic
coma. The most common agents used include
midazolam, lorazepam, diazepam, and alprazolam.
Benzodiazepines exert their sedative and
anticonvulsant effects by potentiating the action
of -aminobutyric acid (GABA) at the GABAA
receptor. The use of benzodiazepines may also
help alleviate emergence reactions that may occur
with the use of ketamine. Prolonged high-dose
continuous infusions of preservative-containing
midazolam may result in metabolic acidosis,
which occurred in the Wisconsin patient, due to
the benzyl alcohol content.29 Similarly, and likely
to a greater extent, the propylene glycol and
benzyl alcohol content of the intravenous
lorazepam formulation may contribute to lactic
acidosis and renal failure. If prolonged high-dose
continuous infusions are anticipated, preservative-
free midazolam should be used to minimize these
adverse effects. Diazepam or alprazolam may be
employed if intermittent intravenous or oral
sedation is sufficient.
If sufficient sedation is not achieved with
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ketamine in combination with a benzodiazepine,
a barbiturate may be added as adjunct therapy.
In the Wisconsin patient, phenobarbital was
added to the patient’s medical therapy to
maintain burst suppression. In the treatment of
other patients with rabies, thiopental sodium and
pentobarbital have been used.25 The barbiturates
have a mechanism of action similar to that of the
benzodiazepines, although they bind to a
different site on the GABAA receptor. They also
have the ability to inhibit glutamate and may
have the potential to directly activate the GABA
receptor chloride channels. Due to the lack of
specificity in the mechanism and sites of action
of barbiturates, the drug class has a greater
toxicity potential and lower margin of safety.34
Barbiturate use in treatment of human rabies
should be limited to allow the host to mount an
immune response to the infection, as these agents
are thought to display immunosuppressant
effects through inhibition of T-cell activation.35
This inhibition is dose dependent (loading doses
should be avoided) and occurs to a greater extent
with the use of thiopental and pentobarbital.
Propofol has also been used in maintaining a
therapeutic coma for rabies cases.25 Like
benzodiazepines and barbiturates, propofol
potentiates the inhibitory function of GABA at
the GABAA receptor.36 It is highly lipophilic, with
a rapid onset similar to that of barbiturates and a
very short duration. Propofol is rapidly metabo-
lized in the liver and may undergo extrahepatic
metabolism as well.34, 37 Propofol is only
available as an intravenous lipid formulation, so
patients should have serum triglyceride levels
monitored in the setting of prolonged infusions.
Long-term and/or high-dose propofol infusions
may also lead to propofol infusion syndrome,
characterized by metabolic acidosis, rhabdomy-
olysis, cardiac failure, and renal failure, which
may be of particular concern in the pediatric
population. Propofol also has more pronounced
cardiovascular effects compared with the
aforementioned agents. Propofol may cause
profound hypotension due to vasodilation and a
decrease in cardiac contractility.34 These actions
may warrant discontinuation of the infusion in
patients who are unable to maintain adequate
pressures, especially during the later stages of
clinical rabies when cardiac complications may
ensue. Two patients with rabies who had been
previously treated with propofol had no EEG
activity after initiation of propofol.31 Due to the
adverse effects and limitations associated with
the use of propofol in patients with rabies, its use
is not recommended by the Milwaukee Protocol.
The duration of maintaining a therapeutic
coma may vary from patient to patient. As
recommend by the Milwaukee protocol,
discontinuation of sedation and analgesia should
occur when patients have mounted an adequate
immune response by evidence of anti-rabies titers
in the CSF exceeding 1:1024 by indirect
immunofluorescence assay or 1:40 by rapid
fluorescent focus inhibition test.31 Conversely,
sedation may be discontinued if the patient has
progressed to denervation of cardiac tissue,
indicated by a lack of heart rate or blood pressure
variability over a 24-hour period. At this point,
the rabies virus has caused significant neuronal
dysfunction and continuation of care may be
considered futile.
Antiviral Therapy
A number of antiviral agents have been
employed in the treatment of human rabies. In
combination with a therapeutic coma, antivirals
should aid in viral clearance and allow the
patient to recover. These agents include ribavirin,
amantadine, interferon alfa, and acyclovir.29, 38 As
previously mentioned, no one treatment regimen
has been consistently successful in eliminating
the rabies virus in humans. Current literature
strongly advises against the use of antiviral
monotherapy in the aggressive management of
rabies due to concerns of resistance and ineffec-
tiveness; therefore, at least two antiviral agents
should be used.28
Ribavirin is a purine nucleoside analog that
inhibits viral messenger RNA production and
contributes to RNA mutations. Ribavirin is
commercially available only as an inhalation
powder for solution (reconstituted for nebulization)
and as an oral formulation with a bioavailability
of approximately 50%. Oral absorption of
ribavirin is increased when taken with high-fat
meals. In several rabies cases, including the
Wisconsin survivor, ribavirin was administered
intravenously as an investigational drug.28, 29
Ribavirin may cause hemolysis, mitochondrial
toxicity, and pancreatitis, all of which occurred in
the Wisconsin patient.29 In the Wisconsin
patient, ribavirin was initiated with a loading
dose of 33 mg/kg followed by a maintenance dose
of 16 mg/kg every 6 hours. Due to toxicity, the
dose was reduced to 8 mg/kg for nine doses
before discontinuation. The efficacy of ribavirin
in the treatment of rabies has yet to be proven.
In a study of mice infected with rabies, ribavirin
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did not demonstrate any antiviral activity.39 A
study conducted in four human patients with
rabies in Bangkok, Thailand, found the use of
both intravenous and intrathecal ribavirin to be
of no benefit.40 In a review of the 32 U.S. rabies
cases reported from 1980–1996, antiviral therapy,
including ribavirin, interferon alfa, and acyclovir,
did not change the duration of illness before
death.38 Due to a lack of evidence supporting its
efficacy, the use of ribavirin is not recommended
for the treatment of rabies.31
Amantadine is an antiviral agent that exerts
its actions by preventing viral uncoating
through the inhibition of the viral M2 protein.
In vitro, amantadine displays inhibitory effects
against rabies infection.41 However, to our
knowledge, no human studies have been
conducted with the use of amantadine for the
treatment of rabies. Of five patients who
underwent the Milwaukee Protocol or modifi-
cations of the protocol in 2006 and 2007, all
received amantadine without success.25 Because
amantadine may also exhibit neuroprotective
effects through NMDA antagonism, as indicated
by its use in the treatment of Parkinson’s
disease, enterally administered amantadine 2.5
mg/kg every 12 hours or 100 mg every 12 hours
( if > 40 kg) is recommended by the Milwaukee
Protocol.31 The use of interferon alfa and
acyclovir are not recommended for the treatment
of rabies. No evidence exists to support the use
of either agent in the treatment of rabies, and
interferon alfa may possess neurotoxic effects.29
Considerations for Use of the Milwaukee Protocol
Although the use of a therapeutic coma in
combination with antiviral agents may have
contributed to the beneficial outcomes in the
case of the young Wisconsin patient, her survival
may have been confounded by the possibility of
infection with a less virulent rabies strain. The
possibility of a very low inoculum also exists
since the virus was likely transmitted when she
sustained a 5-mm bat bite wound at a distal site
on her left index finger.29 Eighteen other
reported cases since the Wisconsin survivor have
attempted the Milwaukee Protocol, or slight
deviations of it, with limited success.5, 25
Although the rabies virus or antigen was never
isolated from any of the previous rabies
survivors, serum and CSF samples all contained
rabies antibodies. The presence of antibodies in
CSF is not consistent with previous vaccination,
confirming the diagnosis of rabies in these
patients. Recently, a 15-year-old Brazilian male
was the first survivor to have the rabies virus
isolated before initiation of the Milwaukee
Protocol.
The survival of a limited number of rabies
victims, only one of whom had the rabies virus
detected, may indicate the presence of an
unidentified viral strain that may not possess the
virulence to completely evade the human
immune system. These findings may also
indicate a genetic variation in the host immune
system that enables the host to more readily clear
the rabies virus. Conversely, these findings could
be related to the effectiveness of postexposure
prophylaxis in five of the seven survivors and the
Milwaukee Protocol in the case of the two recent
survivors. The explanation for failure of the
Milwaukee Protocol in 16 patients may be due to
a combination of the time interval between
inoculation with the virus and protocol
initiation, or deviations from the protocol. In the
five cases published before 2008 that used the
Milwaukee Protocol, more than 8 weeks lapsed
between inoculation with the virus and initiation
of the protocol in four patients (the original
survivor began treatment at 4 wks).25 The fifth
patient began treatment with the Milwaukee
Protocol 4 weeks after viral exposure; however
HRIG was given, which may have interfered with
the host’s immune response to the virus. Details
of the exact regimens used in the remaining 13
cases have yet to be published, so speculation
regarding treatment failure cannot be made.
Based on the beneficial outcomes of the
Milwaukee Protocol in the Wisconsin and Brazilian
patients and the lack of successful alternatives, the
implementation of the Milwaukee Protocol may
be appropriate in certain cases. Rabies victims in
whom the protocol may be effective include
those who are healthy, immune competent and of
young age, as was the case for both the Wisconsin
and Brazilian survivors. Due to the high rate of
mortality associated with the rabies virus
regardless of treatment, patients and families
must be aware of the likelihood of negative
neurologic outcomes and treatment failure that
may result.
Conclusion
The most common mode of rabies transmission
in the United States is the silver-haired bat or the
eastern pipistrelle, and the incidence of rabies in
these bat populations is on the rise. Individuals
at high or continuous risk for exposure should
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undergo preexposure prophylaxis. If an exposure
to the rabies virus is suspected, individuals
should undergo assessment for postexposure
prophylaxis at a local emergency department as
soon as possible. Once an individual develops
clinical signs of rabies, effective treatment
options are limited, and the disease is nearly
100% fatal. Both clinicians and the public need
to be cognizant of the disease and its transmission,
the clinical manifestations of rabies, proper
exposure prevention measures, preexposure
prophylaxis regimens in individuals at high risk
for exposure to rabies, and prompt initiation of
postexposure prophylaxis regimens after possible
exposure to the virus. Resources for additional
information on human rabies are provided in
Appendix 1.
References
1. Jackson AC. Recovery from rabies. N Engl J Med 2005;
352(24):2549–50.
2. Centers for Disease Control and Prevention. Rabies—2008.
Available from http://www.cdc.gov/rabies/. Accessed December
16, 2008.
3. Amsden JR, Warmack TS, Gubbins PO. Zoonoses. In:
Schumock GT, Dunsworth TS, Brundage DM, eds.
Pharmacotherapy self-assessment program. Kansas City, MO:
American College of Clinical Pharmacy, 2004:1–42.
4. Centers for Disease Control and Prevention. Recovery of a
patient from clinical rabies—Wisconsin, 2004. MMWR Morb
Mortal Wkly Rep 2004;53(50):1171–3.
5. Bergquist L. Milwaukee journal sentinal. Brazilian boy with
rabies in recovery. November 16, 2008. Available from
http://www.jsonline.com/features/health/34532044.html.
Accessed December 22, 2008.
6. Rupprecht CE, Gibbons RV. Prophylaxis against rabies. N Engl
J Med 2004;351(25):2626–35.
7. Hemachudha T, Laothamatas J, Rupprecht CE. Human rabies:
a disease of complex neuropathogenetic mechansims and
diagnostic challenges. Lancet Neurol 2002;1:101–9.
8. Leung AK, Davies HD, Hon KL. Rabies: epidemiology,
pathogenesis, and prophylaxis. Adv Ther 2007;24(6):1340–6.
9. Messenger SL, Smith JS, Rupprecht CE. Emerging epidemiology
of bat-associated cryptic cases of rabies in humans in the
United States. Clin Infect Dis 2002;35(6):738–47.
10. Srinivasan A, Burton EC, Kuehnert MJ, et al. Transmission of
rabies virus from an organ donor to four transplant recipients.
N Engl J Med 2005;352(11):1103–11.
11. Jackson AC. Rabies. Neurol Clin 2008;26:717–26.
12. Meslin FX. Rabies as a traveler’s risk, especially in high-
endemicity areas. J Travel Med 2005;12 (suppl 1):S30–40.
13. Manning SE, Rupprecht CE, Fishbein, D, et al. Human rabies
prevention—United States, 2008: recommendations of the
advisory committee on immunization practices. MMWR Morb
Mortal Wkly Rep 2008;57(RR-3):1–28.
14. Sanofi Pasteur. Imovax rabies (rabies vaccine) package insert.
Swiftwater, PA; 2005.
15. Centers for Disease Control and Prevention. Rabies vaccine
supply situation, 2009. Available from http://www.cdc.gov/
rabies/news/RabVaxupdate.html. Accessed April 13, 2009.
16. Novartis. RabAvert (rabies vaccine) package insert. Marburg,
Germany; 2004.
17. Fishbein DB, Sawyer LA, Reid-Sanden FL. Administration of
human diploid-cell rabies vaccine in the gluteal area [letter]. N
Engl J Med 1988;318(2):124.
18. Anonymous. Red book, 2008 ed. Montvale, NJ: Thomson
Healthcare, 2008.
19. Eremeeva ME, Dasch GA. CDC travelers’ health yellow book:
rickettsial infections, 2008. Available from http://wwwn.
cdc.gov/travel/yellowBookCh4-Rickettsial.aspx. Accessed
November 19, 2008.
20. Talecris Biotherapeutics. HyperRAB S/D (human rabies
immune globulin) package insert. Irmo, SC; 2008.
21. Sanofi Pasteur. Imogam Rabies HT (human rabies immune
globulin) package insert. Lyon, France; 1999.
22. Centers for Disease Control and Prevention. Bats and rabies: a
public health guide, 2008. Available from http://www.cdc.gov/
rabies/bats.html. Accessed November 19, 2008.
23. Centers for Disease Control and Prevention. Recommendation
of the immunization practices advisory committee (ACIP)
rabies prevention—United States, 1984. MMWR Morb Mortal
Wkly Rep 1984;33(28):393–408.
24. World Health Organization. Technical report series. WHO
expert consultation on rabies, 2005. Available from http://www.
who.int/rabies/931/en/index.html. Accessed November 19,
2008.
25. McDermid RC, Saxinger L, Lee B, et al. Human rabies
encephalitis following bat exposure: failure of therapeutic
coma. CMAJ 2008;178(5):557–61.
26. Centers for Disease Control and Prevention. ACIP provisional
recommendations for the prevention of human rabies, July 10,
2009. Available from http://www.cdc.gov/vaccines/recs/provisional/
downloads/rabies-july2009-508.pdf. Accessed July 15, 2009.
27. Howdieshell TR, Heffernan D, DiPiro JT. Surgical infection
society guidelines for vaccination after traumatic injury. Surg
Infect 2006;7(3):275–303.
28. Jackson AC, Warrell MJ, Rupprecht CE, et al. Management of
rabies in humans. Clin Infect Dis 2003;36:60–3.
29. Willoughby RE, Tieves KS, Hoffman GM, et al. Survival after
treatment of rabies with induction of coma. N Engl J Med
2005;352(24):2508–14.
30. Hemachudha T, Sunsaneewitayakul B, Desudchit T, et al.
Failure of therapeutic coma and ketamine for therapy of human
rabies. J Neurovirology 2006;12(5):407–9.
31. Medical College of Wisconsin. The Milwaukee protocol, 2007.
Available from http://www.chw.org/display/PPF/DocID/33223/
router.asp. Accessed December 22, 2008.
32. Centers for Disease Control and Prevention. Human rabies—
Indiana and California, 2006. MMWR Morb Mortal Wkly Rep
2007;56(15):361–5.
33. Lockhart BP, Tordo N, Tsiang H. Inhibition of rabies virus
transcription in rat cortical neurons with the dissociative
anesthetic ketamine. Antimicrob Agents Chemother
1992;36(8):1750–5.
34. Trevor AJ, White PF. General anesthetics. In: Katzung BG, ed.
Basic and clinical pharmacology, 10th ed. New York: McGraw-
Hill, 2007:395–411.
35. Humar M, Pischke SE, Loop T, et al. Barbiturates directly
inhibit the calmodulin/calcineurin complex: a novel
mechanism of inhibition of nuclear factor of activated T cells.
Mol Pharmacol 2004;65(2):350–61.
36. Trapani G, Altomare C, Liso G, Sanna E, Biggio G. Propofol in
anesthesia. Mechanism of action, structure-activity relationships,
and drug delivery. Curr Med Chem 2000;7(2):249–71.
37. Evers AS, Crowder CM, Balser JR. General anesthetics. In:
Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman’s the
pharmacological basis of therapeutics, 11th ed. New York:
McGraw-Hill, 2006:341–68.
38. Noah DL, Drenzek CL, Smith JS, et al. Epidemiology of
human rabies in the United States, 1980 to 1996. Ann Intern
Med 1998;128(11):922–30.
39. Bussereau F, Picard M, Blancou J, Sureau P. Treatment of
rabies in mice and foxes with antiviral compounds. Acta Virol
1988;32(1):33–49.
40. Warrell MJ, White NJ, Looareesuwan S, et al. Failure of
interferon alfa and tribavirin in rabies encephalitis. BMJ
1989;299(6703):830–3.
41. Superti F, Seganti L, Pana A, Orsi N. Effect of amantadine on
rhabdovirus infection. Drugs Exp Clin Res 1985;11(1):69–74.
1194
PREVENTION AND TREATMENT OF RABIES Nigg and Walker 1195
Appendix 1. Resources for Information on Human Rabies
Sponsor Web Site Telephone Number
Sanofi Pasteur www.sanofipasteur.com (800) 822-2463
Centers for Disease Control and Prevention www.cdc.gov/rabies (404) 639-1050
Novartis Vaccines and Diagnostics www.novartis-vaccines.com (510) 655-8730
State Rabies Consultation Contacts www.cdc.gov/rabies/staterabiespoclist.html Telephone numbers for
each state may be found
at Web site
Talecris Biopharmaceuticals www.talecris.com (919) 316-6300
